Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by bluebird bio, Inc.

< Previous 1 2 Next >
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces September Investor Events
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces Receipt of Expected Notices from Nasdaq
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces Second Quarter 2024 Results Call Date
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Appoints O. James Sterling as Chief Financial Officer
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene Therapy
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces Receipt of Expected Notice from Nasdaq
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.